

Fecal Microbiota Transplantation in Axial Spondyloarthritis

NCT06451588

Status	RECRUITING
Phase	Phase 2
Sponsor	University Hospital of North Norway
Enrollment	99 participants

Key Eligibility Criteria

Inclusion (5)

- Axial Spondyloarthritis according to the ASAS classification criteria
- Active disease defined as ASDAS e2.1 with elevated CRP e4 OR active inflammation on MRI within the last 3 months
- Onset of axial SpA within last 10 years
- Unsatisfactory relief of NSAIDs
- On stable immunomodulatory treatment (TNFi, IL17i or JAKi) the last 3 months

Exclusion (20)

- Planned dose adjustment or change in immunomodulatory treatment the next 90 days
- Disease or disorder with life expectancy of <5 years
- Severe immune deficiency (acquired, congenital or due to medication)
- Previous treatment with FMT
- Regular use of opioids with the exception of codeine and tramadol
- ... and 15 more (see full listing online)

Locations (1 total)

University Hospital North Norway, Tromsø, Norway

<https://clinicaltrials.gov/study/NCT06451588>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).